Form 4: CFO Robert Dickey IV Reports Vyome Holdings Stock Acquisition

Vyome Holdings, Inc. CFO Robert Dickey IV reported the acquisition of 762 common shares following the merger with Vyome Therapeutics, Inc.

Summary

• Robert Dickey IV, Chief Financial Officer of Vyome Holdings, Inc., reported the acquisition of 762 shares of the company's common stock.
• This transaction occurred on August 15, 2025, as a direct result of the merger between Raider Lifesciences Inc. (a wholly owned subsidiary of the Issuer) and Vyome Therapeutics, Inc.
• The merger, governed by an Agreement and Plan of Merger dated July 8, 2024, resulted in Vyome Therapeutics surviving as a subsidiary of the Issuer.
• Upon the closing of the Merger, the Issuer, previously known as HIND, was renamed "Vyome Holdings, Inc."
• Each 5,000 shares of Vyome Therapeutics common and preferred stock were converted into 1 share of Vyome Holdings, Inc. common stock.
• Mr. Dickey received 762 shares of Vyome Holdings, Inc. common stock in exchange for 3,810,000 shares of common stock of Vyome Therapeutics pursuant to the Merger Agreement.

Sentiment

Score: 7

Explanation: The filing reports the expected outcome of a merger, which is generally a positive strategic move for the company. The CFO's acquisition of shares through this process aligns his interests with the company's future. No negative information is present.

Positives

• The completion of the merger between Vyome Holdings, Inc. (formerly HIND) and Vyome Therapeutics, Inc. indicates a strategic consolidation and potential for growth.
• The reporting person, a key executive, now holds direct beneficial ownership in the newly structured entity, aligning his interests with shareholders.

Future Outlook

No specific forward-looking statements or guidance are provided in this Form 4 filing beyond the completion of the merger.

Management Comments

• "Under the terms of the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the 'Merger Agreement'), by and among the Issuer, Raider Lifesciences Inc., a wholly owned subsidiary of the Issuer ('Merger Sub'), and Vyome Therapeutics, Inc. ('Vyome Therapeutics'), on August 15, 2025, Merger Sub merged with and into Vyome Therapeutics, with Vyome Therapeutics surviving the merger as a subsidiary of the Issuer (the 'Merger')."
• "Upon the closing of the Merger, each share of common and preferred stock of Vyome Therapeutics, was converted into the right to receive 1 share of the Issuer's common stock for every 5,000 shares of Vyome Therapeutics."
• "As a result of the Merger, the Issuer was renamed 'Vyome Holdings, Inc.' and Vyome Therapeutics continued under its name as Vyome Therapeutics, Inc."
• "The reporting person received 762 shares of the Issuer's common stock in exchange for 3,810,000 shares of common stock of Vyome Therapeutics pursuant to the Merger Agreement."

Industry Context

This filing indicates a consolidation within the life sciences or pharmaceutical sector, where smaller entities (Vyome Therapeutics) are acquired by larger or publicly traded companies (Vyome Holdings, Inc.) to integrate technologies, pipelines, or market access. Such mergers are common strategies for growth and expansion in the industry.

Corporate Governance

Stakeholder Impact

• Shareholders of Vyome Therapeutics had their shares converted into Vyome Holdings, Inc. common stock, changing their investment vehicle and potentially its valuation basis.
• Shareholders of HIND (now Vyome Holdings, Inc.) will see the company's strategic focus and asset base altered by the acquisition of Vyome Therapeutics, potentially impacting future share value.
• Employees of Vyome Therapeutics will continue under the new corporate ownership as Vyome Therapeutics, Inc. operates as a subsidiary, suggesting continuity in operations.

Key Dates

Recommendation

This Form 4 reports a mandatory disclosure of an insider's stock acquisition following a merger. While the merger itself is a significant corporate event that could be price-sensitive, this specific filing merely reports the expected outcome for an executive. It does not provide new information about the merger's financial impact or future prospects beyond what would have been disclosed in the merger announcement itself. Therefore, it confirms an expected event rather than signaling a new catalyst for immediate price movement. Investors would likely 'hold' based solely on this filing, awaiting broader financial updates or strategic insights from the combined entity.

Keywords

Vyome Holdings, HIND, Vyome Therapeutics, Merger, Stock Acquisition, Form 4, SEC Filing, Robert Dickey IV, Chief Financial Officer, Corporate Governance, Ownership Change